What question did this study set out to answer?

Evaluate the safety, pathologic response, and relapse rates of neoadjuvant and adjuvant pembrolizumab in patients with resectable locally advanced, HPV-unrelated head and neck squamous cell carcinoma.

July 14, 2020Clinical Cancer ResearchOpen Access

Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial

View Full Paper

Ask AI

Bookmark

Authors

RURavindra UppaluriBrigham and Women's Hospital KCKatie M. CampbellUniversity of California, Los Angeles AEAnn Marie EgloffBrigham and Women's Hospital

Discussion

Member takes

Implication

Multicenter phase II trial demonstrates safety and tumor response with perioperative pembrolizumab in resectable HPV-unrelated head and neck cancer, suggesting reduced relapse rates.

Key Points

Evaluate the safety, pathologic response, and relapse rates of neoadjuvant and adjuvant pembrolizumab in patients with resectable locally advanced, HPV-unrelated head and neck squamous cell carcinoma.
Conducted a multicenter, phase II clinical trial assessing perioperative pembrolizumab.
Enrolled patients diagnosed with resectable, locally advanced, HPV-unrelated head and neck squamous cell carcinoma.
Pembrolizumab demonstrated a favorable safety profile, yielding a 44% overall pathologic response rate and a 0% pathologic complete response rate.
The 1-year relapse rate among patients with high-risk pathology was lower than historical control rates.

Cite This Study

Uppaluri et al. (2020) studied this question.

synapsesocial.com/papers/69d80b4145af6083e6ae2af7 https://doi.org/10.1158/1078-0432.ccr-20-1695

View Full Paper

Ask AI

Bookmark

Implication

Multicenter phase II trial demonstrates safety and tumor response with perioperative pembrolizumab in resectable HPV-unrelated head and neck cancer, suggesting reduced relapse rates.

Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider